Geron Q4 2019 Earnings Report
Key Takeaways
Geron Corporation reported a net loss of $29.1 million, or $0.15 per share, for the fourth quarter of 2019. The company ended the year with $159.2 million in cash and marketable securities.
Completed the imetelstat program transition.
Assembled an in-house team with a proven track record in drug development.
Advanced imetelstat into late-stage development with the opening of the IMerge Phase 3 clinical trial in lower risk myelodysplastic syndromes.
Plans to complete enrollment in IMerge, announce a decision regarding potential late-stage development plans for myelofibrosis by mid-year, and commence a proof of concept study in additional hematologic myeloid malignancies in 2020.
Geron
Geron
Forward Guidance
For fiscal year 2020, the Company expects its operating expense burn to range from $70 to $75 million.
Positive Outlook
- Continue the IMerge clinical trial in 2020.
- Commence a proof of concept study in 2020.
- Validation of supply chain vendors for the manufacturing of imetelstat.
- Further interactions with the FDA in connection with the planned submission of Phase 3 trial design proposals in MF.
- Discussion regarding a potential regulatory approval path in MF.